Literature DB >> 10673085

Interferon therapy in patients with chronic hepatitis C and schistosomiasis.

S M Kamal, M A Madwar, T Peters, R Fawzy, J Rasenack.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10673085     DOI： 10.1016/s0168-8278(00)80207-x

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  11 in total

1.  Efficacy and safety of a novel pegylated interferon alpha-2a in Egyptian patients with genotype 4 chronic hepatitis C.

Authors:  Alaa Awad Taha; Ahmad El-Ray; Maged El-Ghannam; Bahaa Mounir
Journal:  Can J Gastroenterol       Date:  2010-10       Impact factor: 3.522

2.  Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response.

Authors:  S M Kamal; A A El Tawil; T Nakano; Q He; J Rasenack; S A Hakam; W A Saleh; A Ismail; A A Aziz; M Ali Madwar
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

Review 3.  Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6.

Authors:  Vasilios Papastergiou; Stylianos Karatapanis
Journal:  World J Clin Cases       Date:  2015-03-16       Impact factor: 1.337

Review 4.  PEGylation of interferon-β-1a: a promising strategy in multiple sclerosis.

Authors:  Bernd C Kieseier; Peter A Calabresi
Journal:  CNS Drugs       Date:  2012-03-01       Impact factor: 5.749

5.  Schistosomiasis does not affect the outcome of HCV infection in genotype 4-infected patients.

Authors:  Walaa R Allam; Ahmed Barakat; Zainab Zakaria; Gehan Galal; Tamer S Abdel-Ghafar; Mohamed El-Tabbakh; Nabiel Mikhail; Imam Waked; Sayed F Abdelwahab
Journal:  Am J Trop Med Hyg       Date:  2014-03-10       Impact factor: 2.345

6.  Gastrointestinal complications of schistosomiasis.

Authors:  T W Schafer; B R Hale
Journal:  Curr Gastroenterol Rep       Date:  2001-08

7.  Prevalence and clinical presentations of hepatitis C virus among patients admitted to the rheumatology ward.

Authors:  Ayman El Garf; Bassel El Zorkany; Rasha Gheith; Hala Sheba; Geilan Abdel Moneim; Kamal El Garf
Journal:  Rheumatol Int       Date:  2011-07-27       Impact factor: 2.631

8.  Hepatitis C comorbidities affecting the course and response to therapy.

Authors:  Abdel-Rahman El-Zayadi
Journal:  World J Gastroenterol       Date:  2009-10-28       Impact factor: 5.742

9.  European vs. Egyptian HCV-4 patients with elevated baseline HCV RNA, treated with PEG-IFN-α2a and ribavirin: the role of rapid and early virologic response.

Authors:  Dimitrios Dimitroulopoulos; Ioannis Elefsiniotis; Christos Pavlidis; Dimitrios Xinopoulos; Klisthenis Tsamakidis; Stamatina Patsavela; Dimitrios Kypreos; Ageliki Ferderigou; Dimitrios Korkolis; Sotirios Koutsounas; Georgios Saroglou; Emmanouil Paraskevas
Journal:  Hepat Mon       Date:  2010-09-01       Impact factor: 0.660

10.  Impact of PIVKA-II in diagnosis of hepatocellular carcinoma.

Authors:  Nadia I Zakhary; Sherif M Khodeer; Hanan E Shafik; Camelia A Abdel Malak
Journal:  J Adv Res       Date:  2013-01-11       Impact factor: 10.479
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.